Molecular Warehouse, backed by Oxford Technology, has a disruptive, patented biosensor technology designed to enable people to monitor their health using their smartphones. Since their last raise, has had patents granted, and signed a partnership with an international Pharma company.
Our vision is to create a world where most diseases are prevented, by giving people the ability to monitor and manage their health using their smartphones, anywhere, anytime.
We have used synthetic biology to re-engineer the most successful personal diagnostic system, the glucose monitor, which millions of diabetic patients use every day, to be able to detect many other diseases.
Initial applications currently in development target chronic kidney disease, which affects almost 10% of the population worldwide, hemophilia, chronic stress, vitamin D levels, and acute pancreatitis.
Our innovative system is protected by six international patents, and we have unique proprietary assets in synthetic biology, electronics, software algorithms, and data encryption and patient privacy.
KEY PROGRESS SINCE LAST CROWDCUBE ROUND:
> Signed a partnership with an international Pharma company, which included a £215,000 upfront fee and contains over £10m in technical- and sales-based milestone payments
> Developed fully working pre-manufacturing prototype of our Bluetooth-enabled test reader
> Moved to automated manufacturing for our test strips
> Recruited 6 new employees and moved to purpose-built laboratories at the Surrey Research Park
> Filed one new patent, and had two patents granted in USA and one granted in Europe
> Successfully passed ISO13485 & ISO9001 level 1 audit